^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSI-H/dMMR

    i
    Related biomarkers:
    Expression
    Mutation
    Others
    Related tests:
    Apply
    Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (NCT02997228)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/19/2018
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    PD-L1 • MSI • MLH1 • MSH6 • MSH2
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (NCT02912559)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/16/2017
    Primary completion :
    04/02/2025
    Completion :
    04/02/2025
    MLH1 • MSH6 • MSH2 • CD4
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical
    A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20) (CheckMate 8KX) (NCT03656718)
    Phase 1/2
    Bristol-Myers Squibb
    Completed
    Last update posted :
    02/20/2025
    Initiation :
    10/29/2018
    Primary completion :
    09/07/2022
    Completion :
    09/12/2024
    MSI
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)
    A Study of SGN-EGFRd2 in Advanced Solid Tumors (SGNEGFRd2-001) (NCT05983133)
    Phase 1
    Seagen Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    11/14/2023
    Primary completion :
    07/31/2027
    Completion :
    09/30/2028
    EGFR • ALK • MSI
    |
    EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    PF-08046052
    Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (NRG-GY025) (NCT05112601)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    06/02/2022
    Primary completion :
    04/30/2026
    Completion :
    04/30/2026
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Patients With Colorectal Cancer (BGB-A317-214) (NCT05116085)
    Phase 2
    BeiGene
    Active, not recruiting
    Last update posted :
    02/18/2025
    Initiation :
    01/26/2022
    Primary completion :
    09/26/2023
    Completion :
    01/01/2027
    MSI
    |
    MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr)
    Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers (NCT03190174)
    Phase 1/2
    Sarcoma Oncology Research Center, LLC
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    08/24/2017
    Primary completion :
    12/01/2021
    Completion :
    12/02/2021
    MSI
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)
    Utomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer (NCT03290937)
    Phase 1
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    12/27/2017
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    MSI
    |
    MSI-H/dMMR • RAS mutation
    |
    Erbitux (cetuximab) • irinotecan • utomilumab (PF-05082566) • Datalai (cetuximab biosimilar)
    A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors (NCT05904496)
    Phase 1
    BeiGene
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    07/19/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    TMB • MSI
    |
    TMB-H • MSI-H/dMMR
    |
    Tevimbra (tislelizumab-jsgr) • BGB-30813
    Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) (NCT05845450)
    Phase 2
    Gruppo Oncologico del Nord-Ovest
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    05/11/2023
    Primary completion :
    05/01/2026
    Completion :
    05/01/2028
    HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1
    |
    HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type
    |
    Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors (ST316-101) (NCT05848739)
    Phase 1
    Sapience Therapeutics
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    06/05/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2027
    PD-L1 • MSI • BRCA
    |
    PD-L1 expression • MSI-H/dMMR • BRCA mutation
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil) • leucovorin calcium • ST316
    Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (NRG-GY031) (NCT05950464)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    12/18/2023
    Primary completion :
    04/30/2026
    Completion :
    04/30/2026
    PIK3CA • MSI • MYC • ARID1A • MUC16 • HEXIM1
    |
    MSI-H/dMMR
    |
    ZEN-3694 • tuvusertib (M1774)
    Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors (NCT04777994)
    Phase 1
    AbbVie
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    03/09/2021
    Primary completion :
    10/01/2026
    Completion :
    10/01/2026
    PD-L1 • MSI
    |
    MSI-H/dMMR
    |
    osunprotafib (ABBV-CLS-484)
    A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. (Keynote E70) (NCT06116136)
    Phase 1/2
    Servier Bio-Innovation LLC
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    08/31/2024
    Primary completion :
    06/10/2026
    Completion :
    06/01/2029
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • S95029
    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (NCT05836584)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    12/06/2023
    Primary completion :
    10/31/2027
    Completion :
    10/31/2027
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors (Iintune-1) (NCT04420884)
    Phase 1/2
    Takeda
    Recruiting
    Last update posted :
    02/12/2025
    Initiation :
    07/22/2020
    Primary completion :
    01/15/2026
    Completion :
    01/15/2026
    PD-L1 • MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • 5-fluorouracil • dazostinag (TAK-676)
    A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (E7386-J081-102) (NCT04008797)
    Phase 1/2
    Eisai Inc.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/11/2019
    Primary completion :
    11/30/2026
    Completion :
    11/30/2026
    EGFR • KRAS • BRAF • MSI
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type
    |
    paclitaxel • Lenvima (lenvatinib) • doxorubicin hydrochloride • E7386
    Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (NCT05464030)
    Phase 1
    EMD Serono Research & Development Institute, Inc.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/04/2022
    Primary completion :
    02/27/2026
    Completion :
    02/27/2026
    MSI
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • leucovorin calcium • precemtabart tocentecan (M9140)
    A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (NCT05544929)
    Phase 1
    Novartis Pharmaceuticals
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    10/26/2022
    Primary completion :
    02/20/2026
    Completion :
    02/20/2026
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115
    Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer (EA2201) (NCT04751370)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    02/08/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    MSI
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer (NRG GY020) (NCT04214067)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    04/09/2020
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Pembroria (pembrolizumab biosimilar)
    PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer (PNACGEC) (NCT05033392)
    Phase 2
    Wan He
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    09/14/2021
    Primary completion :
    12/31/2026
    Completion :
    12/31/2027
    PD-L1 • MSI
    |
    MSI-H/dMMR
    |
    Loqtorzi (toripalimab-tpzi)
    JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors (KEYNOTE-F62) (NCT06108050)
    Phase 1
    Jazz Pharmaceuticals
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    11/07/2023
    Primary completion :
    11/30/2027
    Completion :
    05/31/2028
    BRAF • MSI
    |
    MSI-H/dMMR • BRAF mutation
    |
    Keytruda (pembrolizumab) • JZP898
    A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (NCT06004245)
    Phase 1
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    01/25/2024
    Primary completion :
    12/15/2027
    Completion :
    12/15/2027
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma (NCT05156268)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    01/27/2022
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    TP53 • MSI • POLE
    |
    TP53 mutation • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib)
    A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive (NCT05879822)
    Phase 2
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    10/30/2023
    Primary completion :
    07/22/2026
    Completion :
    07/22/2026
    PD-L1 • MSI
    |
    PD-L1 expression • MSI-H/dMMR
    |
    INCB99280
    Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (CK-301-101) (NCT03212404)
    Phase 1
    Checkpoint Therapeutics, Inc.
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    09/20/2017
    Primary completion :
    11/18/2021
    Completion :
    12/01/2025
    MSI
    |
    MSI-H/dMMR
    |
    Unloxcyt (cosibelimab-ipdl)
    A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors (START-001) (NCT05592626)
    Phase 1/2
    Marengo Therapeutics, Inc.
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    01/04/2023
    Primary completion :
    10/01/2026
    Completion :
    10/01/2026
    KRAS • TMB • MSI • RAS
    |
    KRAS mutation • TMB-H • MSI-H/dMMR • RAS mutation • RAS wild-type
    |
    invikafusp alfa (STAR0602)
    QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (NCT03228667)
    Phase 2
    ImmunityBio, Inc.
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/11/2018
    Primary completion :
    08/31/2029
    Completion :
    12/31/2030
    BRAF • ALK • MSI
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • docetaxel • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    Nivolumab + Docetaxel + ADT in MHSPC Patients with DDRD or Inflamed Tumors (NCT04126070)
    Phase 2
    Xiao X. Wei, MD
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    05/11/2020
    Primary completion :
    10/24/2024
    Completion :
    06/30/2025
    PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension
    A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer (NCT04844073)
    Phase 1/2
    Takeda
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    03/08/2021
    Primary completion :
    09/27/2025
    Completion :
    11/01/2026
    PD-L1 • KRAS • MSI
    |
    MSI-H/dMMR • PD-L1 negative
    |
    TAK-186
    A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma (NCT05147558)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    01/27/2025
    Initiation :
    12/23/2021
    Primary completion :
    12/23/2025
    Completion :
    12/23/2025
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) (NCT03767348)
    Phase 2
    Replimune Inc.
    Recruiting
    Last update posted :
    01/24/2025
    Initiation :
    09/20/2017
    Primary completion :
    12/01/2025
    Completion :
    12/01/2028
    BRAF • MSI
    |
    MSI-H/dMMR • BRAF mutation
    |
    Opdivo (nivolumab) • vusolimogene oderparepvec (RP1)
    Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1) (NCT02723955)
    Phase 1
    GlaxoSmithKline
    Completed
    Last update posted :
    12/27/2024
    Initiation :
    06/23/2016
    Primary completion :
    07/05/2023
    Completion :
    07/05/2023
    MSI • ICOS
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • 5-fluorouracil • pemetrexed • Jemperli (dostarlimab-gxly) • bintrafusp alfa (M7824) • cobolimab (TSR-022) • feladilimab (GSK3359609) • GSK3174998
    A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator) (NCT06331598)
    Phase 2
    Hoffmann-La Roche
    Withdrawn
    Last update posted :
    12/24/2024
    Initiation :
    11/30/2024
    Primary completion :
    10/20/2028
    Completion :
    09/20/2029
    TMB • MSI
    |
    TMB-H • MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    Refining Adjuvant Treatment in Endometrial Cancer Based on Molecular Features (RAINBO) (NCT05255653)
    Phase 2/3
    Leiden University Medical Center
    Recruiting
    Last update posted :
    11/28/2024
    Initiation :
    11/11/2021
    Primary completion :
    01/01/2030
    Completion :
    01/01/2031
    ER • POLE
    |
    ER positive • MSI-H/dMMR • POLE mutation
    |
    Lynparza (olaparib) • cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • megestrol • medroxyprogesterone
    A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation (NCT06039384)
    Phase 1
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    11/28/2024
    Initiation :
    12/28/2023
    Primary completion :
    11/03/2025
    Completion :
    11/03/2025
    EGFR • KRAS • MSI
    |
    KRAS mutation • MSI-H/dMMR • KRAS G12C • RAS wild-type • KRAS G12
    |
    Krazati (adagrasib) • INCB99280
    Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line (DOMENICA) (NCT05201547)
    Phase 3
    ARCAGY/ GINECO GROUP
    Recruiting
    Last update posted :
    11/25/2024
    Initiation :
    04/15/2022
    Primary completion :
    04/01/2026
    Completion :
    10/01/2029
    MSI
    |
    MSI-H/dMMR
    |
    carboplatin • paclitaxel • Jemperli (dostarlimab-gxly)
    Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors (KEYNOTE-E58) (NCT04041310)
    Phase 1/2
    Nouscom SRL
    Active, not recruiting
    Last update posted :
    11/20/2024
    Initiation :
    10/21/2019
    Primary completion :
    04/30/2025
    Completion :
    11/30/2026
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • NOUS-209